London Stock Exchange Group delivered a solid FY2025. But for investors, the key questions remain: can LSEG sustain ASV growth, defend its financial data moat, and turn AI from a potential threat into a long-term growth driver?

DaVita’s Q4 2025 results were solid, but FY2025 was a mixed year. Revenue improved, adjusted EPS rose, but treatment volumes stayed weak.

Fresenius Medical Care delivered strong Q4 2025 results and improved meaningfully in FY2025 versus FY2024. But with reimbursement tailwinds fading and new investments rising, 2026 looks like a transition year.

Adyen and PayPal 2025 in-depth analysis covering Q4 2025 results, full-year 2025 performance and 2026 outlook.

Evolution AB faced challenges in Q3 due to regulatory issues in Asia and cybersecurity concerns. However, its global growth, strong margins, and solid long-term fundamentals indicate a more resilient outlook than the current share price reflects.

Adyen’s share price fell on tariffs and FX headwinds, but its long-term fundamentals remain strong.